Construction and validation of a prognostic model based on 11 lymph node metastasis-related genes for overall survival in endometrial cancer.
HMGB3
endometrial cancer
lymph node metastasis
mutation
risk signature
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
28
11
2021
received:
25
09
2021
accepted:
23
12
2021
pubmed:
3
7
2022
medline:
15
12
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
Endometrial cancer (EC) is one of the most common malignant tumors in female reproductive system. The incidence of lymph node metastasis (LNM) is only about 10% in clinically suspected early-stage EC patients. Discovering prognostic models and effective biomarkers for early diagnosis is important to reduce the mortality rate. A least absolute shrinkage and selection operator (LASSO) regression was conducted to identify the characteristic dimension decrease and distinguish porgnostic LNM related genes signature. Subsequently, a novel prognosis-related nomogram was constructed to predict overall survival (OS). Survival analysis was carried out to explore the individual prognostic significance of the risk model and key gene was validated in vitro. In total, 89 lymph node related genes (LRGs) were identified. Based on the LASSO Cox regression, 11 genes were selected for the development of a risk evaluation model. The Kaplan-Meier curve indicated that patients in the low-risk group had considerably better OS (p = 3.583e-08). The area under the ROC curve (AUC) of this model was 0.718 at 5 years of OS. Then, we developed an OS-associated nomogram that included the risk score and clinicopathological features. The concordance index of the nomogram was 0.769. The survival verification performed in three subgroups from the nomogram demonstrated the validity of the model. The AUC of the nomogram was 0.787 at 5 years OS. Proliferation and metastasis of HMGB3 were explored in EC cell line. External validation with 30 patients in our hospital showed that patients with low-risk scores had a longer OS (p-value = 0.03). Finally, we revealed that the most frequently mutated genes in the low-risk and high-risk groups are PTEN and TP53, respectively. Our results suggest that LNM plays an important role in the prognosis, and HMGB3 was potential as a biomarker for EC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Endometrial cancer (EC) is one of the most common malignant tumors in female reproductive system. The incidence of lymph node metastasis (LNM) is only about 10% in clinically suspected early-stage EC patients. Discovering prognostic models and effective biomarkers for early diagnosis is important to reduce the mortality rate.
METHODS
METHODS
A least absolute shrinkage and selection operator (LASSO) regression was conducted to identify the characteristic dimension decrease and distinguish porgnostic LNM related genes signature. Subsequently, a novel prognosis-related nomogram was constructed to predict overall survival (OS). Survival analysis was carried out to explore the individual prognostic significance of the risk model and key gene was validated in vitro.
RESULTS
RESULTS
In total, 89 lymph node related genes (LRGs) were identified. Based on the LASSO Cox regression, 11 genes were selected for the development of a risk evaluation model. The Kaplan-Meier curve indicated that patients in the low-risk group had considerably better OS (p = 3.583e-08). The area under the ROC curve (AUC) of this model was 0.718 at 5 years of OS. Then, we developed an OS-associated nomogram that included the risk score and clinicopathological features. The concordance index of the nomogram was 0.769. The survival verification performed in three subgroups from the nomogram demonstrated the validity of the model. The AUC of the nomogram was 0.787 at 5 years OS. Proliferation and metastasis of HMGB3 were explored in EC cell line. External validation with 30 patients in our hospital showed that patients with low-risk scores had a longer OS (p-value = 0.03). Finally, we revealed that the most frequently mutated genes in the low-risk and high-risk groups are PTEN and TP53, respectively.
CONCLUSIONS
CONCLUSIONS
Our results suggest that LNM plays an important role in the prognosis, and HMGB3 was potential as a biomarker for EC patients.
Identifiants
pubmed: 35778922
doi: 10.1002/cam4.4844
pmc: PMC9741985
doi:
Substances chimiques
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4641-4655Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Pathol Res Pract. 2019 Aug;215(8):152475
pubmed: 31178227
BMC Med Res Methodol. 2013 Mar 06;13:33
pubmed: 23496923
Acta Obstet Gynecol Scand. 2004 Jun;83(6):586-90
pubmed: 15144342
J Pathol. 2020 Mar;250(3):336-345
pubmed: 31829441
Comput Struct Biotechnol J. 2014 Nov 15;13:8-17
pubmed: 25750696
J Exp Clin Cancer Res. 2020 Nov 13;39(1):243
pubmed: 33187536
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
J Cancer. 2020 Feb 3;11(8):2139-2149
pubmed: 32127941
Cancer Cell Int. 2019 Nov 14;19:296
pubmed: 31807118
Front Oncol. 2020 Jan 21;9:1508
pubmed: 32039004
Curr Probl Cancer. 2021 Apr;45(2):100660
pubmed: 33012523
Int J Gynecol Cancer. 2018 Feb;28(2):260-266
pubmed: 29194195
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
J Cell Physiol. 2020 Apr;235(4):3438-3446
pubmed: 31621076
Stat Med. 2004 Jul 15;23(13):2109-23
pubmed: 15211606
Eur J Cancer. 2012 Sep;48(14):2282-91
pubmed: 22244827
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Cancer Med. 2020 May;9(10):3522-3536
pubmed: 32170852
Front Oncol. 2021 Mar 08;11:630905
pubmed: 33763366
Chem Biol Interact. 2019 Feb 25;300:73-81
pubmed: 30639441
Cancer Cell Int. 2020 May 24;20:183
pubmed: 32489319
Cancer Manag Res. 2019 Jul 24;11:6959-6969
pubmed: 31413636
Genomics. 2021 Jul;113(4):2032-2044
pubmed: 33915245
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Blood. 2003 Aug 15;102(4):1298-306
pubmed: 12714519
Biomed Pharmacother. 2019 Jul;115:108939
pubmed: 31079003
Cancer Cell Int. 2019 Apr 16;19:100
pubmed: 31015800
Int J Biol Sci. 2019 Jan 1;15(1):208-220
pubmed: 30662360
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9996-10004
pubmed: 31799669
Mod Pathol. 2012 Aug;25(8):1106-16
pubmed: 22481283
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13783-8
pubmed: 16945912
Oncol Lett. 2019 Oct;18(4):4221-4229
pubmed: 31516617
Oncol Lett. 2016 Jan;11(1):323-329
pubmed: 26870211
Med Sci Monit. 2020 Aug 04;26:e925147
pubmed: 32748897
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Int J Mol Sci. 2019 Mar 09;20(5):
pubmed: 30857319
Front Cell Dev Biol. 2021 Oct 12;9:721676
pubmed: 34712660
Gynecol Oncol. 2017 Jan;144(1):107-112
pubmed: 27789083
Cancer Med. 2022 Dec;11(23):4641-4655
pubmed: 35778922
Histol Histopathol. 2000 Jul;15(3):813-24
pubmed: 10963125
Cancer Manag Res. 2019 May 31;11:5075-5089
pubmed: 31213919
BMC Cancer. 2014 Feb 11;14:78
pubmed: 24512546
Cancer Res. 1999 Feb 1;59(3):551-7
pubmed: 9973199
Acta Neuropathol. 2020 Feb;139(2):243-257
pubmed: 31768671
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Cell Death Dis. 2020 Nov 23;11(11):1009
pubmed: 33230171